OneSpaWorld's AI-First Strategy Sets Sail: From Cruise Spa Operator to Tech-Enabled Wellness Platform

Q2 beat and guidance raise as AI yield optimization, prebooking of medi-spa, and peptide optionality redefine growth.

OSW · Earnings Call · 2026-07-29

A Record Quarter, but the Real Story Is the Pivot

OneSpaWorld's second quarter delivered its 21st consecutive record total revenue and adjusted EBITDA, with revenue up 9% to $261.2 million and adjusted EBITDA up 13% to $34.4 million. But the numbers only tell half the story. The call marked a concrete shift from a traditional cruise spa operator into a technology-enabled wellness platform, anchored by a suite of AI initiatives that are already producing measurable revenue uplift.

“AI has been introduced to substantially all of our ships and our corporate office.” — Stephen Lazarus, Chief Financial Officer · 2026-07-29 That single sentence, from CFO Stephen Lazarus, was the genesis of the most substantive update in years. The company named its AI systems—Amanda, AVA, Serena, and Claude—and provided early ROI metrics, something it had explicitly deferred for two quarters.

AI: From Pilot to Production

Amanda, the yield-optimization engine, launched in March and is now on 188 vessels. The machine-learning recommendations are most impactful with less experienced managers, delivering a 4% service revenue uplift. Adoption is near 99%. This is not futuristic tinkering; it's production software driving top-line gains.

The response to the first question is correct. And as it relates to the second part of the question... the impact we feel ultimately is more on the revenue side than on the cost side.
Stephen Lazarus, Chief Financial Officer · 2026-07-29

That revenue-first orientation is consistent with the company's asset-light model and its ability to insulate itself from cost-side shocks. Meanwhile, AVA, the agentic assistant, autonomously resolves 96% of support tickets, and Serena, the guest-facing chatbot, handles nearly half of all sessions outside business hours. These are early wins, but they validate the AI initiative investments.

The company is also using AI to expand its prebooking engine. “We plan to introduce new Serena capabilities to further increase efficiency.” — Stephen Lazarus, Chief Financial Officer · 2026-07-29 And critically, for the first time, Medi Spa and acupuncture are now available on the prebook platform—a missing piece that CEO Leonard Fluxman says will elevate the prebook percentage. Prebooked revenue grew 14% in the quarter, with forward bookings up 20%.

Prebooking and Product Mix: The Next Growth Levers

The prebooking expansion directly addresses a long-standing gap. In the April call, Fluxman noted they were considering including medi-spa in prebooking—this quarter they executed. “which we're starting to consider whether we can include some of that in the prebooking menu.” — Leonard Fluxman, Chief Executive Officer · 2026-04-29 Now they have. The product revenue deceleration, a concern for analysts, was explained by the shift toward medi-spa modalities (growing 17% but with virtually no retail attach) and by the UK/Italy reorganization. This is not weakness; it's a calculated mix shift toward higher-margin services.

The other forward-looking catalyst is GLP-1 and peptide offerings. Fluxman said they haven't introduced them yet but expect to in 2027 once regulations allow. “We have not introduced GLP-1s on board yet. That's not to say we won't.” — Leonard Fluxman, Chief Executive Officer · 2026-07-29 Given the company's position as a premium wellness provider, this could be a significant revenue stream, especially with the growing demand for weight-management therapies.

Financials and Guidance: Confidence Backed by Cash

The company raised full-year guidance to $1.018–$1.038 billion revenue and $130–$140 million EBITDA, representing ~10% growth at the midpoint. That confidence is underpinned by a strong balance sheet: $4 million in CapEx, up sharply as they invest in AI and fleet expansion. Total liquidity stood at $91.6 million.

The market has rewarded the stock modestly (+9.5% over 90 days), but it remains ~7% below its July peak. The AI-driven strategy, if it scales as management suggests, could re-rate the multiple. With 208 ships and 4,664 personnel, the operational leverage is substantial. The question now is whether the revenue uplift compounds—and whether the prebooking and peptide optionality turn into tangible growth.